NCT07594496

Brief Summary

This study evaluates the prevalence of cannabis withdrawal and the clinical manifestations of cannabis withdrawal syndrome in patients hospitalized for BMT or CAR-T therapy.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
58mo left

Started Feb 2026

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress5%
Feb 2026Feb 2031

Study Start

First participant enrolled

February 18, 2026

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 11, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 18, 2026

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2031

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2031

Last Updated

May 18, 2026

Status Verified

May 1, 2026

Enrollment Period

5 years

First QC Date

May 11, 2026

Last Update Submit

May 11, 2026

Conditions

Malignant Solid NeoplasmHematopoietic and Lymphatic System Neoplasm

Outcome Measures

Primary Outcomes (2)

  • Prevalence of cannabis withdrawal

    Descriptive statistics will be utilized to summarize cannabis withdrawal prevalence.

    Up to 1 year

  • Severity of withdrawal symptoms

    Assessed by the Cannabis Withdrawal Scale (CWS), a self-report instrument used measures the intensity of 19 cannabis withdrawal symptoms over the last 24 hours. Each item is rated on a 10-point Likert scale where 0=not al all and 10=extremely. Items are rated twice, first for intensity of symptom and then for negative impact on daily activity. Withdrawal symptom scores range from 0 to 190, with higher scores reflecting greater intensity of withdrawal symptoms.

    Daily for first 4 days of hospitalization

Secondary Outcomes (1)

  • Mortality Rate

    Up to 1 year

Study Arms (1)

Observational

Patients complete surveys and have their medical records reviewed on study.

Other: Non-Interventional Study

Interventions

Non-Interventional StudyOTHER

Non-interventional study

Observational

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients admitted for BMT or CAR-T therapy

You may qualify if:

  • All adult patients admitted for BMT or CAR-T therapy

You may not qualify if:

  • Individuals unable to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States

Location

Related Links

Study Officials

  • Osama A. Abulseoud, MD

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

  • Sondra Schultz, MD

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 11, 2026

First Posted

May 18, 2026

Study Start

February 18, 2026

Primary Completion (Estimated)

February 28, 2031

Study Completion (Estimated)

February 28, 2031

Last Updated

May 18, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations

US(1)